Epizyme to Present Clinical Data on NHL Treatment at ASH Lymphoma Conference

Epizyme to Present Clinical Data on NHL Treatment at ASH Lymphoma Conference

Epizyme, Inc., recently announced it will present four abstracts at the upcoming American Society of Hematology (ASH) Conference on Lymphoma Biology. The abstracts report data from its clinical development program of tazemetostat in patients with advanced B-cell and other types of non-Hodgkin lymphoma (NHL).

Tazemetostat is an orally administered, small molecule EZH2 inhibitor, to treat multiple types of hematological malignancies and genetically defined solid tumors, that is currently in Phase 2 trials to identify efficient and accelerated pathways for treatment.

In previous studies, tazemetostat demonstrated meaningful clinical activity and acceptable safety in patients with hematological malignancies and genetically defined solid tumors.

The ASH conference will be held in Colorado Springs, Colorado, from June 17–21. According to a press release, the company’s presentations are:

  • Vincent Ribrag, MD, Institut Gustave-Roussy, Paris, France, “EZH2 as a target for non-Hodgkin lymphoma and beyond: tazemetostat experience; from bench to bedside and back to the bench,” on June 21, at 10:20 a.m.–10:50 a.m. Mountain Time.
  • Michael Thomenius, PhD, Epizyme, “Tazemetostat treatment drives wild-type and mutant EZH2 DLBCL cell lines to a cell fate decision between apoptosis or differentiation (Poster #39),” on June 19, at 3:45 p.m.–5:15 p.m. Mountain Time.
  • Franck Morschhauser, MD, PhD, Centre Hospitalier Régional Universitaire de Lille, Lille, France, “Initial report from a phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Poster #98),” on
    June 20, at 3:45 p.m.–5:15 p.m. Mountain Time.
  • Christopher Plescia, Epizyme, “Chromatin flow cytometry based assessment of H3K27me3 pharmacodynamics in blood from diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients following exposure to the EZH2 inhibitor tazemetostat reveals disparate response profiles in specific PMBC subpopulations (Poster #38),” on June 20, at 3:45 p.m.–5:15 p.m. Mountain Time.

Epizyme also announced plans to soon start additional clinical assessments of tazemetostat, including a combination trial with R-CHOP (a chemotherapy treatment) and a combination trial with an immune checkpoint inhibitor in NHL patients, as well as a monotherapy in patients with mesothelioma.

Leave a Comment

Your email address will not be published. Required fields are marked *